Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K report on March 1, 2004, primarily to disclose a press release issued on February 27, 2004. While the 8-K itself does not contain extensive operational or financial details, the attached press release is the key piece of information for investors. Investors should review the press release to understand the specific event or update that Regeneron chose to disclose on that date. The filing indicates that this press release was the sole item of significance under 'Other Events and Regulation FD Disclosure,' suggesting it was a material update requiring public dissemination.
Key Highlights
- 1REGN filed an 8-K on March 1, 2004, reporting an event from February 27, 2004.
- 2The primary purpose of the filing was to disclose a press release issued on February 27, 2004.
- 3The press release is included as Exhibit 99(a) to the 8-K filing.
- 4The filing falls under 'Item 5. Other Events and Regulation FD Disclosure', indicating the press release contained material information.
- 5The company's principal executive offices are located at 777 Old Saw Mill River Road, Tarrytown, NY.
- 6The filing was signed by Stuart Kolinski, Vice President & General Counsel.